Showing 1416 results
-
Press release /Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)[1]…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare…
-
Press release /Three times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi® (ruxolitinib) vs BAT[1] RESPONSE-2 complements data…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase from baseline in HFMSE total score in patients with…
-
Press release /The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of…
-
Press release /Novartis receives funding from Bill & Melinda Gates Foundation for further development of Novartis drug candidate KDU731 for the treatment of cryptosporidiosis Cryptosporidiosis is the…
-
Press release /At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patientsNew active pharmaceutical ingredients facility in North…
-
Press release /In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance[1] Zykadia benefit was also seen…
-
Press release /Cosentyx® delivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in the vast majority of patients and continues to show a favorable safety profile over 4 years[1] New data show…
-
Press release /New inhaled combination for asthma treatment (indacaterol acetate, glycopyrronium bromide and mometasone furoate - IND/GLY/MF) was superior to the standard of care (long-acting beta-agonist/inhaled…